INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
-
Medline Inc. (NASDAQ: MDLN) shareholders should email fletcher@fmoorelaw.com
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) --
What is the Investigation About?
On June 2, 2026, the Federal Drug Administration (“FDA”) published a warning letter dated May 28, 2026 addressed to Medline summarizing “significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]” The FDA further states that Medline “failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications.”
Following this news, the price of Medline stock fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026.
According to a June 3, 2026 Reuters article, the latest FDA warning letter relates to “violations of manufacturing quality standards” and is “the second such action against the [C]ompany in two months.” Further, the Reuters article states that according to the FDA, “the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices.”
If you own Medline Inc. (NASDAQ: MDLN) securities, please contact Fletcher Moore at fletcher@fmoorelaw.com.
You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
MOORE LAW PLLC
30 Wall Street, 8th Floor
New York, NY 10005
fletcher@fmoorelaw.com
www.fmoorelaw.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5a4c71e5-7d75-46f7-bbec-ed2e14fad379
image
Fletcher Moore
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
